CHM 0.00% 1.6¢ chimeric therapeutics limited

Ann: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA, page-43

  1. 774 Posts.
    lightbulb Created with Sketch. 528
    https://library.ehaweb.org/eha/2024/eha2024-congress/4136517/abhishek.maiti.ela026.targeting.of.sirp282B29.immune.cells.results.in.a.high.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Amarker%3D5097%2Afeatured%3D18527

    Dr Maiti presenting positive data from a different phase 1 trial next week at EHA2024.

    https://faculty.mdanderson.org/profiles/abhishek_maiti.html

    Impressive guy. 23 honours and awards listed. This one caught my attention.

    2020 ASCO Endowed Merit Award, ASCO Bristol-Myers Squibb.

    He has played a role in 79 peer reviewed articles.

    This is the same guy who approached us because recent data and synergies with our NK cells were just too compelling.




 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.6¢
Change
0.000(0.00%)
Mkt cap ! $14.29M
Open High Low Value Volume
1.6¢ 1.6¢ 1.6¢ $5.12K 320K

Buyers (Bids)

No. Vol. Price($)
13 973796 1.5¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 617827 2
View Market Depth
Last trade - 14.43pm 13/09/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.